FUNDAMENTALS · Fundamentals · TW Healthcare

AP Biosciences (6945) Fundamentals 2026 — Revenue Analysis | SniperIQ

AP Biosciences (6945) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$9.5B, trading at NT$98.10 on the TWO. This SniperIQ fundamentals page covers AP Biosciences's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$9.5B
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is AP Biosciences's market cap?

AP Biosciences (6945) has a market capitalization of approximately NT$9.5B, trading at NT$98.10 on the TWO. Market cap moves with the live share price.

What is AP Biosciences's P/E ratio?

AP Biosciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is AP Biosciences?

AP Biosciences runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does AP Biosciences pay a dividend?

AP Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is AP Biosciences financially healthy?

AP Biosciences carries a debt-to-equity ratio of 0.05x and a current ratio of 29.94x, with a market beta of -0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is AP Biosciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AP Biosciences (6945) the key facts are: market cap NT$9.5B, 52-week range 59.2-236. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track AP Biosciences's full fundamentals live

Get AP Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Chengdu Easton Biopharmaceuticals (688513) fundamentals · Wakamoto Pharmaceutical (4512) fundamentals · Abivax (ABVX) fundamentals · Create Medic (5187) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons